Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087803473> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W3087803473 endingPage "S626" @default.
- W3087803473 startingPage "S625" @default.
- W3087803473 abstract "Current management of recurrent ovarian cancer (OC) is based on the amount of time between completion of latest platinum-based treatment and relapse. Patients with platinum-free interval (PFI) < 6 mo. are considered to be platinum-resistant (PROC) and to have low response rate (RR) to platinum-based chemotherapy. We searched PubMed database for all prospective and retrospective full-text articles on the treatment of patients with PROC for all years between 01/01/2000 and 01/06/2019 in English. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) tool was used to ensure transparent reporting of the results. Study inclusion criteria were: 1) morphologically confirmed epithelial OC; 2) standard definition of PROC as a disease that recurred within 6 months after completion of platinum-based chemotherapy; 3) treatment with platinum- or non-platinum chemotherapy with agents that are routinely used for OC; 4) no concomitant therapy with targeted or investigational agents; 5) clearly defined RR for patients with PROC and criteria for response assessment. Pooled analysis of outcomes and multiple linear regression analysis were conducted to assess the impact of platinum salts on probability of response. We identified 7156 articles. After the review we selected 197 studies for analysis. Of them, 52 (n = 1320) and 145 (n = 6937) trials assessed efficacy of platinum- and non-platinum chemotherapy. Among patients treated with platinum-based and non-platinum chemotherapy RR was 36.04% (95% CI 33.45-38.63) and 14.85% (95% CI 14.01-15.68) respectively. Pooled median PFS was 7.17 months and 3.30 months respectively. In multiple linear regression model administration of platinum chemotherapy was the strongest predictor of RR [B value 0.503 (p < 0.001)]. Cisplatin (RR 39.9%: 95% CI 35.8-44.0%) and carboplatin (RR 42.3%; 95% CI 37.0-47.6%) were associated with better RR compared to oxaliplatin (RR 28.1%; 95% CI 23.9-32.3). This systematic review shows that patients with 'platinum-resistant' ovarian carcinoma may derive significant benefit from reintroduction of platinum agents and their value should be evaluated in further randomized trials." @default.
- W3087803473 created "2020-10-01" @default.
- W3087803473 creator A5005388500 @default.
- W3087803473 creator A5028263106 @default.
- W3087803473 creator A5029722624 @default.
- W3087803473 creator A5031018187 @default.
- W3087803473 creator A5053996794 @default.
- W3087803473 creator A5059253802 @default.
- W3087803473 creator A5080856237 @default.
- W3087803473 date "2020-09-01" @default.
- W3087803473 modified "2023-10-01" @default.
- W3087803473 title "831P Efficacy of platinum-based chemotherapy in platinum-resistant ovarian cancer: A systematic review with pooled analysis of outcomes" @default.
- W3087803473 doi "https://doi.org/10.1016/j.annonc.2020.08.970" @default.
- W3087803473 hasPublicationYear "2020" @default.
- W3087803473 type Work @default.
- W3087803473 sameAs 3087803473 @default.
- W3087803473 citedByCount "0" @default.
- W3087803473 crossrefType "journal-article" @default.
- W3087803473 hasAuthorship W3087803473A5005388500 @default.
- W3087803473 hasAuthorship W3087803473A5028263106 @default.
- W3087803473 hasAuthorship W3087803473A5029722624 @default.
- W3087803473 hasAuthorship W3087803473A5031018187 @default.
- W3087803473 hasAuthorship W3087803473A5053996794 @default.
- W3087803473 hasAuthorship W3087803473A5059253802 @default.
- W3087803473 hasAuthorship W3087803473A5080856237 @default.
- W3087803473 hasBestOaLocation W30878034731 @default.
- W3087803473 hasConcept C121608353 @default.
- W3087803473 hasConcept C126322002 @default.
- W3087803473 hasConcept C141071460 @default.
- W3087803473 hasConcept C143998085 @default.
- W3087803473 hasConcept C161790260 @default.
- W3087803473 hasConcept C185592680 @default.
- W3087803473 hasConcept C2776694085 @default.
- W3087803473 hasConcept C2779384505 @default.
- W3087803473 hasConcept C2780427987 @default.
- W3087803473 hasConcept C518104683 @default.
- W3087803473 hasConcept C55493867 @default.
- W3087803473 hasConcept C71924100 @default.
- W3087803473 hasConcept C95190672 @default.
- W3087803473 hasConceptScore W3087803473C121608353 @default.
- W3087803473 hasConceptScore W3087803473C126322002 @default.
- W3087803473 hasConceptScore W3087803473C141071460 @default.
- W3087803473 hasConceptScore W3087803473C143998085 @default.
- W3087803473 hasConceptScore W3087803473C161790260 @default.
- W3087803473 hasConceptScore W3087803473C185592680 @default.
- W3087803473 hasConceptScore W3087803473C2776694085 @default.
- W3087803473 hasConceptScore W3087803473C2779384505 @default.
- W3087803473 hasConceptScore W3087803473C2780427987 @default.
- W3087803473 hasConceptScore W3087803473C518104683 @default.
- W3087803473 hasConceptScore W3087803473C55493867 @default.
- W3087803473 hasConceptScore W3087803473C71924100 @default.
- W3087803473 hasConceptScore W3087803473C95190672 @default.
- W3087803473 hasLocation W30878034731 @default.
- W3087803473 hasOpenAccess W3087803473 @default.
- W3087803473 hasPrimaryLocation W30878034731 @default.
- W3087803473 hasRelatedWork W2088744974 @default.
- W3087803473 hasRelatedWork W2093802402 @default.
- W3087803473 hasRelatedWork W2164307258 @default.
- W3087803473 hasRelatedWork W2417262672 @default.
- W3087803473 hasRelatedWork W2591732727 @default.
- W3087803473 hasRelatedWork W3047309708 @default.
- W3087803473 hasRelatedWork W3104748582 @default.
- W3087803473 hasRelatedWork W4250083105 @default.
- W3087803473 hasRelatedWork W4254831496 @default.
- W3087803473 hasRelatedWork W4362706485 @default.
- W3087803473 hasVolume "31" @default.
- W3087803473 isParatext "false" @default.
- W3087803473 isRetracted "false" @default.
- W3087803473 magId "3087803473" @default.
- W3087803473 workType "article" @default.